WallStSmart

Alibaba Group Holding Ltd (BABA)vsNextTrip Inc (NTRP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alibaba Group Holding Ltd generates 20357668% more annual revenue ($1.02T vs $5.03M). BABA leads profitability with a 10.1% profit margin vs -290.0%. BABA earns a higher WallStSmart Score of 64/100 (C+).

BABA

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 5.0Value: 9.3Quality: 6.5
Piotroski: 2/9Altman Z: 2.02

NTRP

Avoid

23

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.7Quality: 3.5
Piotroski: 3/9Altman Z: -8.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BABAUndervalued (+59.5%)

Margin of Safety

+59.5%

Fair Value

$375.80

Current Price

$116.30

$259.50 discount

UndervaluedFair: $375.80Overvalued
NTRPUndervalued (+80.5%)

Margin of Safety

+80.5%

Fair Value

$16.12

Current Price

$1.65

$14.48 discount

UndervaluedFair: $16.12Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BABA6 strengths · Avg: 9.2/10
Market CapQuality
$275.57B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4910/10

Growing faster than its price suggests

EPS GrowthGrowth
104.1%10/10

Earnings expanding 104.1% YoY

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

P/E RatioValuation
17.8x8/10

Attractively priced relative to earnings

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

NTRP1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
946.0%10/10

Revenue surging 946.0% year-over-year

Areas to Watch

BABA4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.9%4/10

2.9% revenue growth

Operating MarginProfitability
1.0%3/10

Operating margin of 1.0%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Free Cash FlowQuality
$-18.10B2/10

Negative free cash flow — burning cash

NTRP4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$24.31M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-681.0%2/10

ROE of -681.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BABA

The strongest argument for BABA centers on Market Cap, PEG Ratio, EPS Growth. PEG of 0.49 suggests the stock is reasonably priced for its growth.

Bull Case : NTRP

The strongest argument for NTRP centers on Revenue Growth. Revenue growth of 946.0% demonstrates continued momentum.

Bear Case : BABA

The primary concerns for BABA are Revenue Growth, Operating Margin, Piotroski F-Score.

Bear Case : NTRP

The primary concerns for NTRP are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

BABA profiles as a value stock while NTRP is a hypergrowth play — different risk/reward profiles.

NTRP carries more volatility with a beta of 1.59 — expect wider price swings.

NTRP is growing revenue faster at 946.0% — sustainability is the question.

NTRP generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

BABA scores higher overall (64/100 vs 23/100). NTRP offers better value entry with a 80.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alibaba Group Holding Ltd

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Alibaba Group Holding Limited, also known as Alibaba Group and Alibaba.com, is a Chinese multinational technology company specializing in e-commerce, retail, Internet, and technology. Founded on 28 June 1999 in Hangzhou, Zhejiang, the company provides consumer-to-consumer (C2C), business-to-consumer (B2C), and business-to-business (B2B) sales services via web portals, as well as electronic payment services, shopping search engines and cloud computing services. It owns and operates a diverse portfolio of companies around the world in numerous business sectors.

NextTrip Inc

CONSUMER CYCLICAL · TRAVEL SERVICES · USA

Neurotrope, Inc., a biopharmaceutical company, is focused on developing a product platform for the treatment of Alzheimer's disease. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?